Psychedelics Today Psychedelics Today

In this episode – the first in the 2024 series of Vital Psychedelic Conversations – David interviews Pierre Bouchard, LPC: Vital instructor and lead trainer for the Congregation for Sacred Practices; and Kara Tremain, ACC: recent Vital graduate-turned-instructor, somatic practitioner, and growth and development coach. 
In this series, we pair up a Vital instructor with a current or previous student as a way of showcasing different (and aligned) perspectives on what they feel is most vital for the psychedelic space to be discussing, while also highlighting their experiences with Vital, our 12-month training program. The next cohort begins September 17 and we're accepting applications now.  
As they are both are passionate about somatic work, they discuss: 
The power of somatics in showing people how much our bodies and nervous systems matter, and how our thoughts are often not the main driver How ketamine or MDMA can help with somatic work How somatic sound can be, through music for journeys, sound bowls, or tuning forks: Can just the right frequency create magic? How somatic work is not solely about resolving trauma, but also about learning to conduct energy and use one's body as a tuning apparatus and more!
For links, head to the show notes page. 

In this episode, Kyle interviews Alex Belser, Ph.D. and Bill Brennan, Ph.D.: psychologists, psychedelic researchers, authors, and co-creators of the EMBARK model, a framework for psychedelic therapy. 
When Belser and Brennan worked together at Cybin, they canvassed the field of psychedelic research and saw very little reporting (if any) of the manuals researchers were using, so they created the EMBARK model as a "big tent" framework – a way to understand what patients were going through from the perspective of six different clinical domains, where the clinician can go deeper into whichever domain is needed based on their specific skill sets. The EMBARK model has been used in two randomized controlled trials to date, and its corresponding book, EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person (co-authored by Belser and Brennan), was released in April. 
They discuss: 
The six domains and four ethical care cornerstones that make up EMBARK, as well as the many proposed change mechanisms that come into play Concerns over facilitators stepping aside and letting the medicine do the work: How much of a factor is someone's presence in the room? How much smaller, "little t" traumas can affect people – trauma doesn't always come from a single hallmark event The need for facilitators to be trained well (and trauma-informed), as it's nearly impossible to tell when an adverse outcome is coming and more!

For links, head to the show notes page.

In this episode, special guest host Court Wing interviews Monica Verduzco-Gutierrez, MD: professor and chair of rehabilitation medicine at UT Health San Antonio; Joel Castellanos, MD: co-founder and associate medical director of the Center for Psychedelic Research at UC San Diego; and MaryAnn Welke Lesage: a long COVID survivor who reports experiencing drastic improvement in symptoms after MDMA and psilocybin therapy.
As the world slowly recovers from COVID, many people are seeing continued or new symptoms, and while much is still not understood, these symptoms are being categorized as long COVID: essentially a persistent viral inflammation causing brain fog, headaches, depression, and other hard-to-diagnose symptoms. With estimations of as many as 18% of people in the U.S. experiencing this at one point and 6.8% currently dealing with it, could psychedelics – which can decrease inflammation and reset neural networks – help alleviate these symptoms? 
They discuss: 
How long COVID fits into what we already know about psychedelics, pain, and inflammatory medicine Why MDMA or psilocybin therapy, specifically, can help The importance of physical medicine and rehabilitation (PM&R) and the myriad of tools these physicians have learned to work with Why anecdotal evidence matters towards future research and more! 
For more info, read Lesage's article, "How Psychedelics Became Key to My Long COVID Recovery," as well as the official paper: "Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report."

For more links, head to the show notes page.

In this episode, Joe interviews Sean Lawlor: writer and therapist specializing in ketamine-assisted therapy at Reflective Healing in Fort Collins, CO.
His first book, Psychedelic Revival: Toward a New Paradigm of Healing, will be released on June 4. Written as somewhat of a primer for psychedelics and psychedelic therapy, he talks about how he decided to write the book, how Michael Pollan was an influence, and the importance of making psychedelic literature not boring: Research and statistics are important, but how does one relate to data points when trying to understand something so rich and weird?
He discusses:
Studying philosophy, from Nietzsche and Freud to Jung and William James When a clinical frame or license is important (but can you always trust a license?) How context and interwoven culture matter when differentiating between plant medicines and man-made psychedelics Brian Muraresku’s The Immortality Key and research into ancient Greeks using psychedelics: Why do we place so much importance on proving this? The importance of community, rituals, shared meanings, mythology, and rites of passage
and more! For links, head to the show notes page. 

In this episode, Joe interviews Elliot Marseille, DrPH, MPP: founding director of UC Berkeley’s Collaborative for the Economics of Psychedelics (CEP), a network of health economists and researchers analyzing the economics behind emerging psychedelic-assisted therapies.
In the early days of drug research, efficacy was the leading factor in decision making, but as time has gone on, people are looking much more into the economics of everything: If a government is granted X amount of money, what should they spend it on that will be the most beneficial to the most people? How do you create models for future research and regulations based on the data we have now? Can there be a time in the near future when someone sits before Congress and says, “This is the exact societal cost of not making psychedelic therapy accessible”?
He discusses:
His early work with the SEVA Foundation, studying at the economics behind HIV/AIDS treatments in developing countries His experiences working with Ram Dass and having a big psychedelic journey with Leo Zeff His issues with the recent ICER (Institute for Clinical and Economic Review) report which said they couldn’t endorse MDMA-assisted psychotherapy Why we need more studies tracking people for long periods after psychedelic therapy, specifically analyzing their healthcare utilization over time and more!
For links, head to the show notes page. 

In this episode, Joe interviews two members of The Daschle Group: Founder and CEO, Senator Tom Daschle; and Public Policy Advisor, Charlie Panfil.
As Senator Daschle served in the House of Representatives for eight years (starting in 1978) and the Senate for 21, he was deep in the War on Drugs at its peak, and thankfully, as seen with so many of his constituents in recent years, the data and personal stories of so many healed people has broken through the propaganda and made him a strong advocate for psychedelic-assisted therapy. While minds are changing and progress is happening before our eyes (the majority of substances the FDA is currently researching for psychiatric indications contain some form of psychedelic ingredient), government bureaucracy, a severe lack of communication between the FDA and DEA, and decades of lies are still massive roadblocks. How do we address all of this while advancing research?
They discuss:
The need to develop a partnership between the public and private sectors, mostly for the cost of treatments The DEA’s place in all of this: If they’re essentially a law enforcement agency, why are they involved in the safety and efficacy of medical treatments? The STATES Act, the Breakthrough Therapies Act, and how they can affect research Why we need to move past relying on opioids, and instead, embrace a science-based drug policy and more!

For links, head to the show notes page.